Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
312 Views
Remegen Co Ltd (9995.HK) - Insights About the First Round Enquiry by Shanghai Stock Exchange
This article mainly analyzed RemeGen in terms of its reply to Shanghai Stock Exchange’s first round enquiry, the core products, the pipeline, the...
252 Views
China Healthcare Weekly (Sep17) - A New Round of Rebalancing, Artificial Joints VBP, Genetic Testing
The article mainly analyzed the logic of volume-based purchase (VBP) and healthcare sector rebalancing, the results of centralized procurement of...
261 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
343 Views
InnoCare (诺诚健华) IPO: Momentum Matters but Mind the Limited Upside
InnoCare launched book building to raise up to USD 288 million to list in Hong Kong. In our previous notes, we have covered the company’s key...
419 Views